1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
149.95 USD   +4.97%
07/01INSIDER SELL : Moderna
MT
06/30Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster
MT
06/30U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants -official
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
145.36(c) 142.19(c) 142.81(c) 142.85(c) 149.95(c) Last
4 392 762 3 988 199 2 908 054 5 631 685 4 838 179 Volume
+0.76% -2.18% +0.44% +0.03% +4.97% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash position 2022 18 531 M - -
P/E ratio 2022 5,50x
Yield 2022 -
Sales 2023 9 800 M - -
Net income 2023 3 215 M - -
Net cash position 2023 22 705 M - -
P/E ratio 2023 19,6x
Yield 2023 -
Capitalization 59 644 M 59 644 M -
EV / Sales 2022 1,86x
EV / Sales 2023 3,77x
Nbr of Employees 2 700
Free-Float 90,6%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in... 
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MODERNA, INC.
07/01INSIDER SELL : Moderna
MT
06/30Moderna Files For Canadian Regulatory Approval Of New COVID-19 Booster
MT
06/30U.S. FDA to use existing Omicron booster data to review shots targeting new subvariants..
RE
06/30US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
RE
06/30Tweaked COVID boosters in US must target newer omicron types
AQ
06/30Moderna Seeks Health Canada Nod For New Double-Protection Covid-19 Booster - Global New..
RE
06/30COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna..
RE
06/29BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2
RE
06/29Taiwan to receive first doses of Novavax COVID vaccine this week
RE
06/28Pfizer, Moderna to be ready with BA.1-specific COVID boosters
RE
06/28FDA advisers recommend updating COVID booster shots for fall
AQ
06/27INSIDER SELL : Moderna
MT
06/27US grapples with whether to modify COVID vaccine for fall
AQ
06/27INSIDER SELL : Moderna
MT
06/26Moderna Seeks Swissmedic's Approval Extension For COVID-19 Jab Against Omicron
MT
More news
News in other languages on MODERNA, INC.
07/01VENTE D'INITIÉS : Moderna
06/30Moderna dépose une demande d'approbation réglementaire canadienne pour le nouveau boost..
06/30FDA bittet Impfstoffhersteller um Anpassung auf Omikron-Sublinien
06/30Südkorea erteilt erstmals Zulassung für einheimischen Impfstoff
06/29Taiwan recevra les premières doses du vaccin Novavax COVID cette semaine
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 03/09
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 149,95 $
Average target price 213,67 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031
ALNYLAM PHARMACEUTICALS, INC.-12.58%17 911